Reshaping the HIV treatment and prevention landscape

Strategic collaboration with Halozyme Expands portfolio of long-acting agents ViiV Healthcare 9 H Halozyme Unique partnership aimed at significantly improving patient experience in HIV treatment and PrEP Focused on developing ultra long-acting regimens (3 months plus) Exclusive license in HIV treatment for integrase inhibitors, capsid inhibitors, NRTTI and bNAb Potential in PrEP to increase Cabotegravir dosing interval from every two months to up to six months gsk 79

View entire presentation